Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Sales of Ethical Drugs Up 5.6% in September: Crecon Report
November 11, 2011
- US FDA Accepts Filing for Astellas Pharma’s Mirabegron
November 11, 2011
- Nipro: Net Profits Down 81.5% due to Great East Japan Earthquake
November 11, 2011
- Fuso’s Ordinary and Net Losses were Pushed into Deficit by Quake (April-September 2011)
November 10, 2011
- Asahi Kasei Pharma to Accelerate Coagulant Development, Makes US Venture Wholly-Owned Subsidiary
November 10, 2011
- UCB, Otsuka to Apply for Domestic Approval of RA Drug in 2012
November 10, 2011
- Pharmaceutical Sales Up 0.5% in Bayer AG Jan-Sep Results
November 10, 2011
- Daiichi Sankyo Obtains Brazil Rights for OAB Treatment Uritos
November 10, 2011
- Nippon Shinyaku Increases Both Sales, Profits Driven by Growth of Vidaza
November 10, 2011
- Premium for New Drug Development Should Be Increased: Mr Miyoshi of IMS Japan
November 10, 2011
- Sanofi Expected to Overtake Pfizer as World’s Top Drug Maker in 2012: Evaluate Pharma
November 10, 2011
- Seikagaku to Conduct Add’l PIII Trial for Lumbar Disc Herniation Treatment SI-6603
November 10, 2011
- Toho HD’s Sales Increased to ¥2 Bil. in 1st-Half Driven by Dispensing Pharmacy Business
November 9, 2011
- Toho Holdings' Matsutani Says His Company Will Protect Its Own Prices
November 9, 2011
- Operating Profit Rate for Top-4 Wholesalers Slips to 0.39% in April-September
November 9, 2011
- Astellas, RIKEN to Explore, Jointly Develop Novel Drug Targets for AD
November 9, 2011
- Yakult, LivTech Enter into Option Agreement for Anti-Cancer Monoclonal Antibody Development Program
November 9, 2011
- Towa Pharmaceutical Developing Lipitor Generic Version OD Tablets
November 9, 2011
- Nihon Chouzai Planning to Open 150-200 Stores a Year: President Mitsuhara
November 9, 2011
- CMIC Reports Increases in Sales and Profits Driven by CRO Business
November 8, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…